$3.10
Today
as of Jul 22, 16:40 ET
Last 30 days
Recent Press Releases & News
Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
Overview
52-week range
$2.83
$5.55
10% of range
Avg surprise (last 3)
-19.1%
Avg reaction (last 2)
-6.0%
0% positive
Latest IV / EM
71%
EM ±16.1% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.47 | $-0.54 | +13.0% | +11.3% | -5.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.47 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.57 | $-0.48 | -18.8% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.53 | $-0.35 | -51.4% | — | -6.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.18 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.59 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.51 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.55 | -$0.57 | +3.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-30M | — | $-31M | $-37M | $-35M | — | $-14M | $-15M |
| Net income | $-28M | — | $-28M | $-33M | $-31M | — | $-9M | $-10M |
| EPS (diluted) | $-0.47 | — | $-0.47 | $-0.57 | $-0.53 | — | $-0.16 | $-0.18 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $43M | $65M | $45M | $44M | $75M | $71M | $113M | $76M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $147M | $203M | $220M | $228M | $245M | $277M | $373M | $382M |
| Total assets | $219M | $252M | $288M | $322M | $353M | $393M | $426M | $436M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $46M | $56M | $68M | $78M | $81M | $93M | $96M | $101M |
| Total equity | $174M | $196M | $220M | $244M | $273M | $300M | $330M | $335M |